Retinoblastoma: Etiology, Modeling, and Treatment
Overview
Affiliations
Retinoblastoma is a retinal cancer that is initiated in response to biallelic loss of in almost all cases, together with other genetic/epigenetic changes culminating in the development of cancer. deficiency makes the retinoblastoma cell-of-origin extremely susceptible to cancerous transformation, and the tumor cell-of-origin appears to depend on the developmental stage and species. These are important to establish reliable preclinical models to study the disease and develop therapies. Although retinoblastoma is the most curable pediatric cancer with a high survival rate, advanced tumors limit globe salvage and are often associated with high-risk histopathological features predictive of dissemination. The advent of chemotherapy has improved treatment outcomes, which is effective for globe preservation with new routes of targeted drug delivery. However, molecularly targeted therapeutics with more effectiveness and less toxicity are needed. Here, we review the current knowledge concerning retinoblastoma genesis with particular attention to the genomic and transcriptomic landscapes with correlations to clinicopathological characteristics, as well as the retinoblastoma cell-of-origin and current disease models. We further discuss current treatments, clinicopathological correlations, which assist in guiding treatment and may facilitate globe preservation, and finally we discuss targeted therapeutics for future treatments.
Chen J, Zeng B Int Ophthalmol. 2025; 45(1):73.
PMID: 39934516 DOI: 10.1007/s10792-025-03449-x.
MicroRNAs' Significance in Retinoblastoma Diagnosis and Treatment: The Little Heroes.
Zamani Sani M, Mirzaei M, Mota A, Mohammadian J, Beilankouhi E, Rahmati M Biochem Genet. 2025; .
PMID: 39862293 DOI: 10.1007/s10528-024-10976-2.
Kulbay M, Tuli N, Mazza M, Jaffer A, Juntipwong S, Marcotte E Biomedicines. 2025; 13(1).
PMID: 39857692 PMC: 11762644. DOI: 10.3390/biomedicines13010108.
Bai S, Wang H, Bai Y, Liu P, Bi C Biochem Genet. 2024; .
PMID: 39718722 DOI: 10.1007/s10528-024-10985-1.
Prospects of anti-GD2 immunotherapy for retinoblastoma.
Zhang X, You W, Wang Y, Dejenie R, Wang C, Huang Y Front Immunol. 2024; 15:1499700.
PMID: 39620227 PMC: 11604707. DOI: 10.3389/fimmu.2024.1499700.